CTOs on the Move

Ovac Inc

www.ovac.com

 
Ovac Inc is a Cathedral City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ovac.com
  • 67555 E Palm Canyon Dr Ste C103
    Cathedral City, CA USA 92234
  • Phone: 760.321.9220

Executives

Name Title Contact Details

Similar Companies

AgaMatrix

AgaMatrix is revolutionizing health care. We`ve sold over a million devices, two billion sensors, and we are the first FDA cleared medical device/app that works with iOS. AgaMatrix is an inventor and leader in consumer healthcare technology. With fewer than 150 people, almost 50% in R&D, we develop glucose monitoring and management systems for diabetes. Diabetes related care accounts for 20% of all healthcare spending in the US. Our innovative multidisciplinary technology vision includes iPhone, Android, and web applications supported by a cloud-based, Java back end for data management and exchange between patients and their doctors. Our UI/UX won the prestigious red dot design award. Our proprietary tech platform, protected by 126 granted/pending patents, uses DSP algorithms to double accuracy while reducing cost by 50%. AgaMatrix not only developed the first FDA cleared medical device that connects to an iPhone, but has over a dozen other FDA cleared products, and has sold over 2.5M meters and 3B biosensors. Our products are available in 20,000 retail locations and a worldwide in partnership with Sanofi, the world's largest pharmaceutical company. We`ve been featured by the New York Times and Fast Company, and we work with the world`s largest retailers (Walmart, Kroger, Target) and pharmaceutical companies (Sanofi, Perrigo) to change the way diabetes is treated.

Hospira

Hospira is the world`s leading provider of injectable drugs and infusion technologies. Through our broad, integrated portfolio, we are uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. Through our offering of high-quality, lower-cost generic medications, we continue to help reduce the overall costs of healthcare — to improve both the affordability of care for patients and the financial strength of the global healthcare system. By working with our device customers to integrate technologies at the point of care, we are the partner of choice for improving patient and caregiver safety, clinical outcomes, cost management, as well as caregiver efficiency and effectiveness. Additionally, our One2One™ business is a leading provider of contract manufacturing services to proprietary pharmaceutical and biotechnology companies for formulation development, filling and finishing of injectable pharmaceuticals. At Hospira, we have the opportunity to Make a Difference every day by positively impacting the lives of our customers and patients and delivering value to all of our stakeholders.

Ilshin America

Ilshin America is a Hialeah, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ossur

Ossur is in the business of improving people`s mobility. As a leading global company in non-invasive orthopaedics, we deliver advanced and innovative technologies within the fields of prosthetics, braces, supports and compression therapy. Determined to restore maximum biological function to those in need, Össur has more than thirty years` experience in the design and production of high-tech orthopaedic devices. Our work, however, is as much about people as it is about products. Their comfort, confidence and rehabilitation are central to our endeavors. We never forget that every time we develop a product or service, we are helping someone else to build a better life.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.